Michelle Byrtek

Early Relapse of Follicular Lymphoma After Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Defines Patients at High Risk for Death: An Analysis From the National LymphoCare Study

Carla Casulo, Michelle Byrtek, Keith Dawson et al. · Journal of Clinical Oncology · 2015 · 818 citations · Full text

Outcomes of transformed follicular lymphoma in the modern era: a report from the National LymphoCare Study (NLCS)

Nina D. Wagner‐Johnston, Brian K. Link, Michelle Byrtek et al. · Blood · 2015 · 213 citations · Full text

Effectiveness of First-Line Management Strategies for Stage I Follicular Lymphoma: Analysis of the National LymphoCare Study

Jonathan W. Friedberg, Michelle Byrtek, Brian K. Link et al. · Journal of Clinical Oncology · 2012 · 177 citations · Full text

Randomized Open-Label Phase II Trial of Apitolisib (GDC-0980), a Novel Inhibitor of the PI3K/Mammalian Target of Rapamycin Pathway, Versus Everolimus in Patients With Metastatic Renal Cell Carcinoma

Thomas Powles, Mark R. Lackner, Stéphane Oudard et al. · Journal of Clinical Oncology · 2016 · 125 citations · Full text

Examination of the follicular lymphoma international prognostic index (FLIPI) in the National LymphoCare study (NLCS): a prospective US patient cohort treated predominantly in community practices

Ajay K. Nooka, Chadi Nabhan, Xiaolei Zhou et al. · Annals of Oncology · 2012 · 96 citations · Full text

Lymphoid Neoplasia, National Lymphocare Study, Epidemiology +6